Molecular diagnostic panel for thyroid cancer disease management
Quest homepage

Dr. Reitz describes the findings during an oral presentation at the June 4, 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). View the abstract: Molecular diagnostic panel for thyroid cancer disease management.

Doctor with senior patient providing medical consultation

The test is believed to be the most comprehensive panel clinically available to identify mutations associated with four gene markers indicated by the American Thyroid Association for the clinical management of indeterminate thyroid biopsies.

Doctor smiling with colleague talking to a patient

About 5% to 15% of thyroid nodules detected in the United States are malignant.1 Accurate diagnosis is essential to avoid unnecessary thyroid surgery for benign disease and to select the most appropriate treatment option for cancerous nodules.

Richard E. Reitz, MD

Richard E. Reitz, MD

Dr. Medical Director, Endocrinology San Juan Capistrano,CA USA. More about professional consults.

Physician using smartphone

Online Presentation: Advances in Thyroid Cancer Testing

Drs. Richard Reitz and Frederic Waldman, Medical Directors, Quest Diagnostics Nichols Institute, discuss recent developments in the field of thyroid cancer, in particular the significance of genetic mutations in thyroid cancer.  

mother daughter smiling

Educating Patients

As part of our service, you can access patient education materials to address common patient questions about diseases and tests. Direct your patients to our Diagnostic Testing A-Z page for information about Thyroid cancer diagnostic testing.

healthcare professional using laptop

Quest Diagnostics Interpretive Guides

Find information relating to test selection, utilization, and interpretation. All information is based on peer-reviewed publications, practice guidelines, or other reputable sources.